ANI Pharmaceuticals presents preclinical data on use of Cortrophin Gel

ANI Pharmaceuticals (ANIP) announced preclinical data on the use of Purified Cortrophin Gel in an EAU mouse model. “In a preclinical model of autoimmune uveitis, Cortrophin Gel reduced levels of inflammatory molecules without stimulating an adverse immune response,” said Mary Pao, MD, PhD, Chief Medical Officer of Rare Disease at ANI. “The results further support our understanding of Cortrophin Gel’s mechanism of action.” An experimental autoimmune uveitis mouse model was used to determine the impact of four doses of repository corticotrophin injection. The results showed a significant dose-dependent effect on the suppression of EAU at all doses, with the greatest suppression of EAU at the 400 U/kg dose. RCI also significantly suppressed the production of cytokines implicated in inflammation and immune system activation. Additionally, 400 U/kg Purified Cortrophin Gel treatment suppressed retinal damage caused by EAU, similar to alpha-MSH treatment, compared to placebo.